Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Significant Intercompany Transactions

All significant intercompany transactions have been eliminated. Details of the Company’s subsidiaries are as follows:

Name	Date of incorporation or establishment	Place of incorporation (or establishment) /operation	Percentage of ownership as of December 31, 2020			Percentage of ownership as of December 31, 2019			Principal activities
Sinovac Biotech   (Hong Kong) Limited   (“Sinovac Hong Kong”)	October 2008	Hong Kong		100	%		100	%	International sales   and marketing
Sinovac Biotech Co.,   Ltd. (“Sinovac Beijing”)	April 2001	People’s Republic of China (“PRC”)		73.09	%		73.09	%	Research and   development,   production and   sales of   vaccine   products
Sinovac Life Sciences   Co., Ltd. (“Sinovac LS”)   (formerly Sinovac   Research & Development   Co., Ltd.) *	May 2009	PRC		59.24	%		100	%	Research and   development,   production and   sales of   vaccine   products
Sinovac (Dalian) Vaccine   Technology Co., Ltd.   (“Sinovac Dalian”) **	January 2010	PRC		68	%		67.86	%	Research and   development,   production and   sales of   vaccine   products
Sinovac Biomed Co., Ltd.	April 2015	PRC		100	%		100	%	Distribution of   vaccine products
Sinovac Biotech (Singapore)   Pte. Ltd. ("Sinovac   Singapore")	August 2020	Singapore		100	%		—		International sales   and marketing